Notably, inhibitors targeting programmed death 1 (PD-1), programmed cell death ligand 1 (PD-L1), and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) have been instrumental in managing various cancers [1,2]. This evidence concerns the gene CD274 and cancer.